| dc.description.abstract | Chronic kidney disease (CKD) has an incidence rate of 10-13%. CKD patients have a significantly increased incidence of cardiovascular disease (CVD) mortality. It has been disclosed that complications caused by CVD are the leading cause of death in patients with end-stage renal disease (ESRD). Higher inflammation markers might contribute to the increased complications and mortality rate in these patients. In this study, we aimed to evaluate the effect of curcumin on inflammatory markers of IL-6, CRP, ferritin, and ESR in ESRD patients under hemodialysis patients.
Methods
Forty-two participants were included in this interventional clinical trial. Before any interventions, the blood samples of patients were collected and sent to the lab for further analysis. A daily tab of curcumin (Curcuma, Dineh-iranIran) consisting of 47.5-milligram curcumin was prescribed for patients for four months. After four months, the blood samples of patients were collected and sent to the lab. Hgb, HCT, creatinine, urea, FBS, total cholesterol, triglyceride, ESR, and CRP levels were measured before and after the intervention.
Results
There was a statistically significant difference in serum total cholesterol (p-value= 0.006) and triglyceride (p-value= 0.003) levels before and after the intervention. Despite important changes in inflammatory markers, there was no statistically significant difference in the inflammatory markers before and after the intervention. | en_US |
